UNAIDS welcomes South Africa’s Lenacapavir HIV prevention launch

UNAIDS has welcomed South Africa’s rollout of Lenacapavir as a landmark step in HIV prevention. The injectable is now available at 360 public health facilities across six provinces. The drug has also been added to the national essential medicines list.

South Africa launched the Lenacapavir HIV prevention programme on 6 June 2026. UNAIDS described the development as a landmark achievement for the country. The injectable is currently available at 360 public health facilities in six provinces. Officials have added the drug to South Africa’s essential medicines list. UNAIDS highlighted the rollout as an important measure to expand access to effective HIV prevention options.

Labaran da ke da alaƙa

A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.
Hoton da AI ya samar

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

A new NGO report warns that lingering effects of 2025 US Pepfar funding cuts are undermining South Africa's rollout of the six-monthly HIV prevention injection lenacapavir, despite recent US funding restoration efforts and initial shipments. Community infrastructure losses hinder uptake among high-risk groups, even as rollout begins late May.

An Ruwaito ta hanyar AI

A new combination pill containing bictegravir and lenacapavir shows promise for people with HIV who require complex regimens. The phase three ARTISTRY 1 study found it performed as well as existing multi-pill options. Experts note its impact in South Africa will likely remain limited.

A study published on Monday in Nature Microbiology confirms long-term HIV remission in the «Oslo patient», a 62-year-old man treated for myelodysplasia via stem cell transplant from his brother carrying the CCR5 Delta 32 mutation. He has been off antiretrovirals for four years with no detectable virus. This brings the total to ten patients deemed cured this way.

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi